According to a recent LinkedIn post from Colossal Biosciences, the company is focusing a new de-extinction effort on the bluebuck, an antelope species driven to extinction more than 200 years ago. The post describes a strategy that combines genomics as a blueprint for reconstruction with assisted reproductive technologies such as ovum pick-up and IVF to attempt to re-establish the species.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that the bluebuck initiative is positioned as a platform to develop tools and technologies with broader applicability to conservation. By tying de-extinction work to challenges like habitat fragmentation and declining genetic diversity among African antelopes, the company appears to be signaling potential long-term commercial and partnership opportunities in wildlife genetics, advanced reproductive services, and conservation technology.
For investors, this emphasis on scalable technologies rather than a single-species project could indicate a strategy aimed at building intellectual property and know-how that may be monetized across multiple conservation and biodiversity use cases. If the approach proves technically viable and attracts collaboration with governments, NGOs, and private conservation stakeholders, it could strengthen the company’s position in the emerging de-extinction and conservation genomics segment, though timelines and revenue pathways remain highly speculative.